Advertisement

Topics

Immunotherapy May Become New Standard of Care in Advanced Non-Small Cell Lung Cancer

20:01 EDT 17 Oct 2016 | Cancer Connect

Researchers presented full results of Keytruda® (pembrolizumab) and Opdivo® (nivolumab) in previously untreated advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology annual meeting in Copenhagen. An additional study was also recently published in the New England Journal of Medicine evaluating Keytruda in previously treated patients with advanced NSCLC . Results of […]

The post Immunotherapy May Become New Standard of Care in Advanced Non-Small Cell Lung Cancer appeared first on CancerConnect News.

Original Article: Immunotherapy May Become New Standard of Care in Advanced Non-Small Cell Lung Cancer

NEXT ARTICLE

More From BioPortfolio on "Immunotherapy May Become New Standard of Care in Advanced Non-Small Cell Lung Cancer"

Quick Search
Advertisement
 

Relevant Topics

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...